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ABSTRACT

One of the pathological hallmarks of Alzheimer's disease (AD) is the amyloid plaque deposition
in aging brains by aggregation of amyloid-β (Aβ) peptides. In this study, the effect of chloroplast
derived myelin basic protein (MBP) fused with cholera toxin subunit B (CTB) was investigated
in advanced diseased stage of human and mouse AD brains. The CTB-fusion protein in
chloroplasts facilitates transmucosal delivery in the gut by the natural binding ability of CTB
pentameric form with GM1 receptors on the intestinal epithelium. Further, bioencapsulation of
the MBP within plant cells confers protection from enzymes and acids in the digestive system.
Here, 12-14 months old triple transgenic AD mice were fed with CTB-MBP bioencapsulated in
the plant cells for 3 months. A reduction of 67.3% and 33.3% amyloid levels in hippocampal and
cortical regions, respectively were observed by immunostaining of brain sections with anti- Aβ
antibody. Similarly, 70% decrease in plaque number and 40% reduction of plaque intensity was
observed through thioflavin S (ThS) staining that specifically stains amyloid in the AD brain.
Furthermore, ex vivo 3xTg AD mice brain sections showed up to 45% reduction of ThS stained
amyloid levels when incubated with enriched CTB-MBP in a concentration dependent manner.
Similarly, incubation of enriched CTB-MBP with ex vivo postmortem human brain tissue
sections with advanced stage of AD resulted up to 47% decrease of ThS stained amyloid plaque
intensity. Lastly, lyophilization of plant material facilitates dehydration and long term storage of
capsules at room temperature, in addition to increasing CTB-MBP concentration by 17 fold.
These observations offer a low cost solution for treatment of even advanced stages of the AD by
facilitating delivery of therapeutic proteins to central nervous system to address other
neurodegenerative disease.
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CHAPTER ONE: INTRODUCTION
Alzheimer’s Disease
Alzheimer’s disease (AD), the most prominent form of dementia, has been estimated to
affect 36 million people globally in World’s Alzheimer Report (WAR) 2010 (1), with a projected
increase of up to 115 million at an annual cost of $604 billion. The 2011 WAR report concludes
that up to 28 million people with dementia, lack efficient diagnosis, treatment and care (2),
increasing the “treatment gap” from high to low and middle income countries. Many potential
therapies for inhibiting cognitive AD symptoms are in development including inhibitors to
cholinesterase (3), memantine (4), and other drugs to reduce AD burden. Accumulation of betaamyloid (Aβ) plaques, attrition of neurons and synapses, rapid clearance of Aβ and
neurofibrillary tangles (NFT’s) formation (5, 6) are major challenges in treatment of AD.
Biomarkers can play an important role in therapeutic treatments by detecting the pathology and
biological effects on cerebral amyloid clearance followed by other downstream processes. Early
detection of AD by identification and quantification of in vivo beta-amyloid through ligands
specific to amyloid is a significant advancement. Amyloid imaging has progressed through
positron emission tomography (PET) using Pittsburgh compound B as an amyloid ligand (7, 8).
Along with magnetic resonance imaging (MRI) that correlates neuro-psychological decline in
AD patients (8), other biomarkers facilitate intervention of AD in a large number of patients at
preclinical stages and clinical trials. The cleavage of amyloid precursor protein (APP) produces
Aβ40, Aβ38, Aβ42 and Aβ46 (9), among which Aβ42 aggregates to form extracellular plaques. The
increase in plaque volume leads to loss in synaptic function and neuronal degeneration (10).
Active and passive immunotherapy involves administration of amyloid peptides and anti1

amyloid antibodies respectively to evoke an immune response. Reduction in Aβ levels have been
reported in animal models through active and passive immunotherapies (11, 12). However phase
II clinical trial of the AN1792 Aβ vaccine was discontinued due to side effects and meningoencephalitis observed in ~6% of the immunized AD patients (11, 12). Other medications like
donepezil or acetylcholinesterase offer only suggestive benefits rather than preventing
progression of the disease (13, 14); hence strategies to clear pathologic proteins as the potential
targets for AD are needed.

Myelin Basic Protein
Based on insights from AD pathogenesis, several therapeutic approaches are developed to
reduce amyloid burden. Liao et al. (15) showed the strong interaction of myelin basic protein
(MBP) with Aβ peptides, thereby preventing their assembly into mature amyloid fibrils. The
“classic” isoform of MBP, 18.5kDa besides seizing the cytoplasmic leaflets of myelin
membranes in myelin sheath (16), holds serine proteinase and autocatalytic activity. Moreover, it
accounts for 30% of total myelin protein and represents a major structural component of myelin
sheaths in the central nervous system. Interaction of MBP with Aβ peptides and their prevention
into amyloid fibrils has been shown (17). Furthermore, degrading activity of MBP was
demonstrated by incubation with brain sections of Aβ precursor protein transgenic mice in situ
(15) by binding to Aβ at a site located in the N-terminal domain of MBP. Moreover it has shown
to play an important role in amyloid cytotoxic effects in cortical neurons (18). The effect of MBP
by delivering it in vivo into the brain can be hypothesized to reduce the amyloid plaques as well.
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Blood Brain Barrier
To ensure the regulation of transport of substances inside and outside the brain, complex
and tight intracellular junctions guard the blood brain barrier (BBB). This regulation further
limits the passage of lipophilic molecules, proteins, metabolites across BBB (19). Moreover, the
delivery of drugs intravenously does not offer an advantage for neurodegenerative diseases
because of the prevention of an optimal uptake across BBB. Recently, studies have shown that
polymeric nanoparticles coated with GM1 binding peptide promoted transcytosis as an important
process for BBB penetration (20, 21). Further, receptor mediated endocytosis (RMT) and
internalization is triggered through involvement of caveolae, which is enriched in ganglioside
GM1 (21, 22). Selection of high affinity GM1 binding ligands, like pentavalent CTB address the
process of transcytosis across BBB remarkably. Studies have also shown that CTB can bind to
GM1 on the surface of neurons and enter through endocytosis (23). The fusion of CTB with
therapeutic proteins can offer an optimal delivery system to transport the protein across BBB, in
vivo. Similarly, MBP fused with CTB was hypothesized to cross through receptor mediated
delivery BBB in vivo in mice and degrade Aβ aggregates.

Plant Derived Therapeutic Proteins
To address expensive fermentation systems, molecular farming has been developed as an
alternative new technology for the production of therapeutic proteins. Recently, FDA approved a
carrot cell based system for production of the first human therapeutic protein (24). Expensive
chemical synthesis and purification, delivery using injections, and process of cold storage can be
eliminated by low cost production of recombinant proteins in plants. The two major processes
3

for the derivation of proteins from plants include nuclear and plastid derived transformation.
Plants provide an excellent bioreactor to produce proteins at a low cost and provide antigen
protection by bioencapsulation. Lyophilization process of plant material helps to package
capsules in a particular dosage or size, eliminates microbes and allows keeping plant material at
room temperature for several months without disrupting its functionality (25).

Chloroplast Transformation
Many advantages are offered by chloroplast transformation and genetic engineering. As
each plant cell contains 100 chloroplast organelles and each chloroplast contains up to 100
chloroplast genome; there exists 10,000 copies of chloroplast genome in each plant cells. This
phenomenal copy number helps to achieve high expression of transgene levels by chloroplast
genetic engineering. Up to 72% total leaf protein (26) has been reported for biopharmaceutical
proteins in transgenic chloroplasts. Unlike nuclear transformation, chloroplast genome is not
transferred through pollen, offering gene containment through maternal inheritance (27).
Through site specific homologous recombination in chloroplast genome, positional effect or gene
silencing are prevented. In addition, not only chloroplasts can transcribe polycistronic mRNA of
plastids providing efficient expression of multiple genes, but also process posttranslational
modifications of eukaryotic protein (28). Many genetically engineered plants for expression of
proinsulin (29), insulin and C peptide (30), exendin 4 (25) for treatment of diabetes or blood
clotting factor IX for hemophilia B (31), bacterial antigens like anthrax protective antigen (32),
viral antigens like human papilloma virus L1 (33), dual vaccine to against cholera and malaria
(34) have been expressed ideally in chloroplast system. Moreover, Nicotiana tabacum
4

chloroplasts have served as a bioreactor for its ability to maintain high biomass, and
transformation efficiency. Likewise, edible crop including lettuce are used for transformation not
only because it decreases the production cost but also offer ideal system for oral delivery of
therapeutic proteins. In a similar fashion, generation of transgenic plants for MBP expression
through chloroplast transformation was carried out in this study.

Bioencapsulation and Oral Delivery of Proteins
Oral delivery can be facilitated by bioencapsulation of foreign protein expressed in plant
cells. These cells are ensured protection in the stomach from acids and enzymes. As they meet
microbes in the gut, plant cell proteins are released in circulatory system. Further, lyophilization
of plant cells allows preparation of capsules and long term storage of vaccines at room
temperature, eliminating microbes, cold storage, purification and injections. Oral delivery of
biopharmaceutical proteins and vaccines efficiently across intestinal mucus membrane is
facilitated by GM1 receptors on the intestinal epithelial cells by binding to the CTB half of the
fusion protein. Five B subunits monomers in the cholera toxin (CT) are assembled into a
pentameric ring structure, which binds specifically to oligosaccharide domain of GM1 receptor
(35). Hence, CTB subunit fused to a protein ensures protein delivery to the immune or
circulatory system through a receptor mediated mechanism. Moreover, this study focuses on the
delivery of CTB fusion protein to the brain. To test the delivery of therapeutic protein, MBP
across BBB, MBP was fused with CTB. The GM1 receptors of the brain (36) are anticipated to
cross link with CTB portion of the fusion protein and act as a vehicle to deliver MBP across
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BBB. The concept of bioencapsulation will allow the protein to remain stable and actively
perform its activity of degrading amyloid beta in Alzheimer’s disease brain.
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CHAPTER TWO: MATERIALS AND METHODS

Southern Blot Analysis
Plant genomic DNA Extraction and Restriction Digestion
Total genomic DNA from untransformed wild type and transplastomic lines was
extracted using DNeasy plant mini kit protocol (Qiagen). Extracted genomic DNA was
quantitated using Nanodrop (Biorad), then three micrograms of DNA was digested with Afl III
enzyme. The reaction mixture contained 4 μl of 10X buffer (New England Biolabs), 3µg of plant
genomic DNA, 1μl of enzyme for a final volume adjusted to 40μl with distilled water. The
digestion reaction was incubated at 37°C overnight.
Agarose gel Electrophoresis and Transfer of DNA to Membrane
The digestion of DNA samples was confirmed by running them on a 0.8% agarose gel at
60V. The gel was then rinsed twice with distilled water for 5 min each to facilitate efficient
transfer. To facilitate the binding of radio-labeled probe to the corresponding genomic DNA
fragment, AflIII digested DNA was denatured by soaking the gel in transfer buffer (0.4N NaOH,
1M NaCl) for 20 min. The separated digested genomic DNA in the gel were transferred
overnight by placing it facing the presoaked nylon membrane followed by filter paper and gentle
pressure by stack of paper towels. Weights were placed on top for balance optimal contact
between gel and membrane. Following day, membrane was rinsed with 2X SSC (3M NaCl, 0.3M
sodium citrate) 2 times for 5 min each. Membrane was dried on a filter paper and was cross
linked using GS gene linker UV chamber at C3 setting.
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Hybridization and Autoradiography
After overnight transfer, membrane was prehybridized with 10 ml of QuickHyb
prehybridization solution (Stratgene) at 68°C for 1 hr on a rotary chamber. In the meantime 510μl of the flanking probe was added to 100 μl of salmon sperm DNA, vortexed and heated at
94°C for 5 min. Next, the probe mixture was added to hybridization bottle containing the
prehybridized membrane and incubated for 1 hr at 68°C. Following incubation, the membrane
was washed twice with 25ml of wash buffer 1 (2 X SSC & 0.1% SDS) at room temperature for
15 min each and washed twice with 25ml of wash buffer 2 (0.1X SSC and 0.1% SDS) at 60°C
for 15 min each. The membrane was wrapped in a saran wrap and radioactivity was checked
using a Geiger counter. X-ray film was exposed to the hybridized membrane in dark and kept at 80°C for 12-72 hr depending on the radioactive count. The exposed X-ray film was developed in
a film processor.
Confirmation of Inheritance
The plants that were positive from southern blot analysis were multiplied and transferred
to Jiffy pots (Harris Seeds). After acclimatization in an incubation chamber for about 2 weeks,
plants were transferred to greenhouse for biomass. Seeds from self pollinated transplastomic
plants were collected and germinated in ½ MS media containing 2% (w/v) sucrose and
spectinomycin (500mg/L) along with wild type seeds in culture room to check for inheritance.

Protein Extraction and Bradford Assay
Expression level of CTB fused MBP protein was examined at different time of harvest
and developmental stages. The total leaf proteins of transplastomic plants grown in greenhouse
8

were extracted according to leaf ages such as young, mature and old at different time points 10am, 2pm, and 6pm. The leaf material frozen in liquid nitrogen was then grinded to fine powder
using motor and pestle. In 300µl of plant extraction buffer (100 mM Nacl, 10 mM EDTA,
200mM tris HCl pH 8.0, 0.05% Tween-20, 0.1% SDS, 14 mM βME, 200 mM sucrose, 2 mM
PMSF, 1X protease inhibitor cocktail) 100mg of finely grinded transplastomic leaf was added.
The total leaf protein was homogenized by mixing for 10 minutes at 4°C, followed by
centrifugation at 14,000 rpm for 5 min to obtain the supernatant and pellet fractions. The pellet
was discarded and supernatant was used for quantification. The concentration of the total leaf
protein was determined using the Bio-Rad protein assay dye reagent. The standard curve was
plotted by serial diluting 0.8µg/µl BSA down to 0.05mg/ml. The supernatants were diluted with
water in a ratio of 1:10, 1:20 and 1:40. A 96 well assay plate was used to which 10μl of each
sample and BSA standard was added in duplicates. Bradford dye reagent (200μl) was added to
each well and absorbance was measured at 595 nm using a plate reader.

Western Blot Analysis
To check for expression of CTB-MBP fusion protein, western blot analysis was
performed. The samples were diluted with 2X sample loading buffer (3.55 ml dH20, 1.25 ml
0.5M Tris-HCl pH 6.8, 2.5 ml glycerol, 2 ml 10% SDS, 0.2 ml 0.5% bromophenol blue), boiled
for 10 minutes, centrifuged, loaded on 12% SDS-PAGE gel and ran at 110 V. The proteins were
separated according to their molecular weights. Next, the proteins were transferred to a
nitrocellulose membrane using Bio-Rad electro blotting transfer apparatus at 85 V for 1 hr.
Membrane was then incubated in PTM (PBST with 3.5% dry milk) at room temperature for 1 hr
9

with gentle shake to block non-specific binding. CTB-MBP protein was detected using anti-CTB
rabbit primary polyclonal antibody (Sigma) diluted in PTM (1:12000). The fusion protein was
also probed with rabbit anti-human MBP primary monoclonal antibody (1:1000, Abcam). The
membrane was incubated with respective primary antibodies overnight at 4°C with gentle
shaking. Following day, the membrane was washed twice with PBS-T for 5 min each at room
temperature. Next, goat anti-rabbit IgG conjugated to horse radish peroxidase (HRP) secondary
antibody diluted in PTM (1:4000) was added to the membrane and incubated at room
temperature for 1.5 hr with gentle shaking. Next, membrane was washed thrice with PBS-T for
10 min each followed by a last wash with PBS for 15 min. Supersignal West Pico
chemiluminescent substrate (Thermo Scientific) was added to the membrane and a
chemiluminescent signal was detected on autoradiography film through an automated X-ray film
processor. Similarly native PAGE was carried out with detection of fusion protein in native state
as mentioned above, except that DTT and SDS were removed during preparation of gels, sample
buffer and plant extraction buffer and the samples were not boiled.

Densitometric Studies for Quantification of Protein
For quantification of the CTB-MBP protein, developed X-ray film against
immunoblotted membrane probed with anti-CTB antibody was used for densitometric analysis.
To plot the standard curve for CTB protein, known amounts of CTB (50, 100, and 150 ng) were
loaded for immunoblot analysis. The concentration of CTB-MBP expressed in transplastomic
plants was determined by plotting the detected bands onto the standard curve using the
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Alphaimager and Alpha ease FC software. Thetotal soluble protein % was also calculated using
formula described before (37).

Lyophilization
CTB-MBP frozen material was lyophilized to obtain higher protein concentration by
freeze drying the material using Freezone Benchtop Freeze Dry Systems (Labconco) in vacuum
for 48 hrs at -50oC and 0.036mBar. Following lyophilization, freeze dried leaf material was
grinded using coffee blender (Hamilton Beach) for 2 min at maximum speed (pulse on for 10 sec
and off for 10 sec) then stored under moisture-free condition stored at room temperature. To
check the stability and functionality of the lyophilized protein, proteins were extracted described
above then immunoblot with anti-CTB antibody was conducted and compare its protein
expression to that of fresh weight leaf material.

CTB GM1 Assay
To investigate the proper formation of pentameric structure of CTB-MBP fusion protein,
GM1 (monosialotetrahexosylganglioside) assay was done with soluble proteins extracted from
the CTB-MBP expressing fresh weight and lyophilized leaf material, and purified CTB. . GM1
ganglioside (Sigma G-7461) was coated by incubating 100μl of GM1 (3μg/ml) in bicarbonate
buffer, (15 mM Na2CO3, 35 mM NaHCO3, pH 9.6) at 4ºC overnight. PTM (100μl) was coated as
a control. Plate was washed three times with PBST and distilled water. PTM (200 μl) was added
and incubated for 2 hrs at 37°C for blocking non specific binding. The plate was again washed
three times with PBST and water. Various concentrations of protein extracted from transplatomic
11

and untransformed plants diluted in plant extraction buffer were added to the wells and incubated
overnight at 4°C, including CTB protein as control. Following day, the plate was washed thrice
with PBST and water, and incubated with 1:12,000 dilution of rabbit anti-CTB primary antibody
(Sigma) for 1 hr at 37°C. Following set of washings for three times with PBST and water, the
plate was incubated with 1:4000 dilution of anti-rabbit IgG secondary antibody conjugated to
horse radish peroxidase (Southern biotech, USA) for 1 hr at 37°C. The plate was washed three
times with PBST and water. Then 100μl of TMB (Signal Transduction Products) was added and
kept in dark for 20-30 min depending on the color reaction. The reaction was stopped by adding
50μl of 2N H2SO4. Absorbance was measured at 450 nm by using a microplate reader.

Ex Vivo Studies
Ex vivo brains from 24 months old 3xTg AD mice were received from National Institute of
Aging (NIA), for which 7µm cryostat sections were collected on slides. Seven adjacent sections
were incubated with 25µg or 50µg of 33% purified CTB-MBP plant protein in PBS. Commercial
CTB alone, BSA and untransformed plant protein were also used for concentration-dependent
incubation as controls simultaneously. After 2 days of incubation at 37 oC, sections were stained
with Thioflavin S (ThS, Sigma), imaged and quantified using NIS Elements for Advanced
research software using Nikon Eclipse TE2000-E fluorescence microscope. Threshold intensity
was based on the intensity of background staining in control sections. The selected threshold was
held constant across all experimental sections. Ex vivo post mortem brain tissues from
Alzheimer’s disease patients, processed and received as described before (38) were
deparaffinized and rehydrated to ensure good staining of the tissue. The slides were passed
12

through xylene followed by graded washes with xylene and ethanol, with a final wash of
molecular grade water. Brain sections were incubated with 50µg of CTB-MBP (33% purity)
transplastomic plant or untransformed plant material. After 2 days of incubation at 37oC, sections
were stained with ThS and DAPI to acquire images as described above.

Animal Studies
Oral delivery of 3xTgAD Mice with Bioencapsulated CTB-MBP
The 3xTg AD mice were received from NIA. These mice were derived by microinjecting
two independent transgenes encoding human APP (Sweden) and tau (P301L) into single
embryos harvested from the homozygous mutant PS1 (M146V) knockin (PSI-KI) mice, as
described previously (72). For these studies, 12-14 months old (at the start of study) 3xTg AD
mice were used for oral delivery of CTB-MBP. Animals, housed under pathogen free conditions,
were treated under Instituitional Animal Care and Use Committee-approved protocols. The
lyophilized leaf material for oral dose (31.2ug/300ul/day) of either transgenic (n=10) or NT
(n=4) was delivered three times a week for three months. A set of mice (n=4) were kept unfed.
For the oral delivery experiments, the lyophilized material was prepared by adding 4mL of PBS
to 500mg of lyophilized and powdered CTB-MBP expressing plant material on ice right before
the oral gavage.
Immunohistochemistry and Thioflavin S Staining
On the day of sacrifice, all mice were perfused with saline following which the brains
were removed. One hemisphere of the brain tissue from 3xTg AD mice was prepared for
histological analysis in 4% paraformaldehyde overnight whereas the three brain regions13

cerebellum, hippocampus, and cortex were dissected from the other hemisphere for Aβ
measurements. Brain cryosections (8μm thick) from the coronally mounted other hemisphere of
3xTgAD mice delivered orally with the powdered lyophilized CTB-MBP expressing
transplatomic plants was obtained on slides using microtome slicing system (Fischer). Adjacent
five sections were exposed for 1 hr to PBS containing 0.1% Triton X-100 (Sigma) and 5%
normal goat serum (Invitrogen, Camarillo, CA) to block nonspecific antibody binding, followed
by incubation overnight with primary antibody, poyclonal anti-amyloid beta (1:200 Cell
Signaling # 2454), overnight at 4oC. To test for nonspecific staining by the secondary antibodies,
additional slides were processed in a similar fashion with the primary antibodies excluded. All
slides were then rinsed for 1 hr at room temperature in several changes of PBS and incubated in
the dark for 1 hr at RT in PBS that contained 5% NGS and the fluorescent secondary antibody,
Alexa Fluor 568-conjugated IgG (1:200). Following incubation with secondary antibody, the
cryosections were counterstained with Hoescht 33342 (Invitrogen), images were acquired by
Nikon Eclipse TE2000-E fluorescence microscope. These images were then processed by NIS
Elements for Advanced Research, with the input levels adjusted to span the range of acquired
signal intensities exactly. Statistical analysis for the data was analyzed by single factor ANOVA
Similarly, following PBS rehydration, adjacent five sections were stained with 0.02% ThS in
70% EtOH for 8 minutes. This was followed by rinsing the slides in 50-80% EtOH and distilled
water respectively and cover slipped with DAPI solution for acquiring images as mentioned
before.

14

CHAPTER THREE: RESULTS

Confirmtaion of transgene integration and characterization of CTB-MBP protein
expressed in chloroplasts
Transplastomic chloroplast lines were confirmed by Southern blots conferring site
specific integration of transgene into the spacer region between trnI and trnA genes. Digestion of
untransformed (WT) plant DNA with AflIII showed 4.2kb fragment after hybridizing with 32Plabeled trnI-trnA flanking probe and transplastomic CTB-MBP lines showed only the 6.7kb
fragment, confirming homoplasmy through site specific integration of transgene (Fig. 1a).
Evaluation of foreign gene expression at different developmental stages - young(Y), mature (M)
and old (O) and at time of harvest – 10am, 2pm, 6pm, showed the highest MBP expression in
mature leaves at 6pm (Fig. 1b and 1c). Enhanced translation of gene in the light by psbA
promoter and 5’UTR regions located upstream of MBP gene cassette should contribute to
maximal expression observed later in the evening. Immunoblots probed with CTB (Fig. 1d) and
MBP (Fig. 1e) antibody showed ~28.5kDa fusion protein monomer in CTB-MBP transplasomic
lines. Fresh weight leaves expressed up to 2% of total leaf protein, where a 17 fold enhanced
concentration of the protein was achieved by lyophilization of the plant material (Fig. 1f and j).
Equal loading of protein showed a significant difference in accumulation of CTB-MBP between
fresh and lyophilized materials (Fig. 1f). Moreover immunoblots probed with CTB antibody
showed that lyophilized material maintained stability at room temperature and protection from
degradation over 7 months of duration (Fig. 1g). The functionality of CTB-MBP fusion protein
was evaluated by GM1 ELISA, where the ability of CTB to bind to the GM1 receptors depends
on its pentameric form. GM1 binding assay showed that pentamers of fresh weight and
15

lyophilized CTB-MBP were formed; this confirms proper folding and formation of disulfide
bonds (Fig. 1i). Non-reducing native PAGE immunoblots probed with CTB antibody further
confirmed the native pentameric formation (Fig. 1h) within transgenic chloroplasts, attesting
functionality of CTB-MBP for further in vivo and in vitro studies. Lyophilization process
preserved the folding and disulfide bonds of CTB-MBP protein even after prolonged storage
(Fig. 1j).
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Figure 1: Confirmation of homoplasmy and CTB-MBP protein expression in
transplastomic tobacco
(a) Digestion with AflIII yields 4.2kb and 6.7kb fragments in WT and transplastomic lines
respectively as shown in southern blot analysis. (b, c) Protein analysis showing CTB-MBP
protein expression relative to leaf’s age and time of harvest. (d, e)Western analysis of CTB-MBP
expression in fresh (F) and lyophilized (L) transgenic plant extracts. SDS-PAGE with anti- CTB
antibody (d), Lane 2, 3, 4 - 12.5ng, 25ng, 37.5ng purified CTB standard respectively; lane 5 & 6
- 20ug of F and L respectively. SDS-PAGE with anti-MBP antibody (e), Lane 2 & 3 - 20ug of F
and L respectively. (f) SDS PAGE with anti-CTB antibody for normalization of F and L
transgenic plant protein. Equal quantity (100mg) of F and L samples that were obtained by
adding equal volume of plant extraction buffer (300uL). (g) Western analysis showing long term
stability of CTB-MBP (L) after storage at room temperature for seven months. Lane 1, 2, 4, 5, 7
– 20ug of L in stored at different months, lane 8 – 12.5ng CTB standard. (h) Native PAGE with
anti-CTB antibody. Lane 1- 37.5ng purified CTB standard; lane 2 & 3 - 2ug of F and L
respectively. (i) GM1 ELISA assay for functional pentamers of purified CTB (25ng), transgenic
CTB-MBP protein in 20ug of F, L and WT extracts. (j) Quantification of CTB-MBP protein (mg
of protein/g of total leaf) in F and L plant extracts.
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Reduction of amyloid levels in 3xTgAD mice brains by CTB-MBP incubation
Ex vivo studies of thioflavin S (ThS) stained brain sections (Fig. 2a) from 24 months old
3xTg AD mice showed reduction in amyloid plaques in a concentration-dependent manner when
incubated with chloroplast-derived CTB-MBP. ThS fluorescence reduction from 44-60% was
detected with 2 days incubation with 33% purified 25-50ug of CTB-MBP plant derived protein
in adjacent brain sections (Fig. 2b). Control incubations with protein extract from untransformed
plants, PBS buffer or purified CTB (commercial source) under identical conditions didn’t show
any decrease in ThS intensity. The decreased intensity in CTB-MBP incubated sections as
compared to WT treated or other controls, shows that CTB-MBP at an optimal concentration of
50g is able to break and/or remove the amyloid fragments, thereby reducing their thioflavin S
fluorescence. Data shown is mean ± S.D of values obtained from seven adjacent sections and
evaluated from a total of 63 fluorescence images.
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Figure 2 : Reduction of amyloid plaque load in ex vivo mouse brain tissue sections
incubated with the CTB-MBP chloroplast expressed protein.
(a) Sagittal serial sections of brains from 3xTg AD mice were incubated with 25 and 50g
recombinant CTB-MBP protein partially purified from transgenic leaf extracts or 25 or 50g
commercially available purified CTB for 2 days and then stained with 0.02% ThS solution to
visualize the central dense core of compact amyloid (green) and with DAPI to identify cell nuclei
(blue) by fluorescence microscopy. As controls, adjacent sections were incubated with 25 or
50g of untransformed leaf extracts or saline alone and processed for ThS staining in parallel.
Shown are sections including the hippocampus and cortex of representative 24 -month-old 3xTg
AD mice. (Scale bar: 10um). (b) Quantification of the relative amounts of amyloid plaque load
in the ThS stained sections after incubation with the indicated proteins or saline alone as
described in (a). The mean plaque counts in the DG, CA1 and CA3 hippocampal and cortical
regions per section (in cortex, mantle and pallium regions) were determined with NIS Elements
for Advanced Research. Data shown is mean ± S.D of values obtained from seven adjacent
sections and two fields per section.
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Reduction of amyloid levels in post-mortem human AD brains by CTB-MBP
Ex vivo studies of ThS stained brain sections of post mortem brain tissues from
Alzheimer’s disease patients (Fig. 3a) were conducted with incubation of CTB-MBP chloroplast
expressed protein. An optimal working concentration of 50g of 33% purified CTB-MBP
protein was obtained from ex vivo mice studies. Next, adjacent brain sections stained with ThS
upon 2 days of incubation with 33% purified 50g of CTB-MBP, showed 47.5% ThioS
fluorescence reduction of stained amyloid plaques (Fig. 3B). As observed in ex vivo mice brain
sections, the decreased intensity in CTB-MBP incubated human sections when compared to
untransformed plant extract shows that MBP through its serine proteinase activity was also able
to break down plaques and/or remove the smaller amyloid fragments, thereby reducing their ThS
fluorescence in human tissue as well. Data shown is mean ± S.D of values obtained from
sections of five AD patients and evaluated from a total of 10 fluorescence images.
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Figure 3: Reduction of amyloid plaque in ex vivo post-mortem AD brain tissue sections
incubated with the CTB-MBP chloroplast expressed protein
Sections of the parietal cortex from AD patients (a) were incubated with 50g recombinant
CTB-MBP protein partially purified from transgenic leaf extracts or 50g of partially purified
untransformed leaf material for 2 days and then stained with 0.02% Thioflavin S solution to
visualize the central dense core of compact amyloid (green) and with DAPI to identify cell
nuclei (blue) by fluorescence microscopy. As controls, adjacent sections were incubated with
50g of untransformed wild-type leaf extracts or saline alone and processed for ThS staining in
parallel. (Scale bar: 10um). (b) Quantification of the relative amounts of amyloid plaque load in
the Thio-S stained sections after incubation with the indicated proteins or saline alone as
described in (a). The mean plaque counts per section were determined with NIS Elements for
Advanced Research. Data shown is mean ± S.D of values obtained from sections of five AD
patients and two fields per section.
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Reduction of Amyloid Levels in 3xTgAD mice upon oral delivery of bioecapsulated CTBMBP
The effect of oral delivery for a period of three months with either bioencapsulated CTBMBP (31.2ug/day), untransformed WT plant cells or unfed mice was evaluated in brain sections
of 3xTgAD mice, that were 12-14 months old at the start of this study. Stained adjacent cortex
and hippocampus sections of control and CTB-MBP treated mice stained with the anti-β-amyloid
antibody (Fig. 4a, red) or ThS (Fig. 4b, green) were examined and quantified as described in
methods. Most plaques were found in the hippocampus region, particularly DG, CA1 and CA3
sites, from where they started diffusing to the cortex as the age of mice progresses. Aβ level
reduction of up to 67.3% and 33.4% in hippocampus and cortex, respectively was observed (Fig.
4c) through immunostaining with anti- Aβ antibody upon oral delivery of CTB-MBP. Data
shown is mean ± S.D of values obtained from five adjacent sections from each mouse and
evaluated from a total of 120 fluorescence images. Moreover, ThS staining showed up to 70%
decrease in plaque number and 40% reduction in plaque intensity (Fig 4d) which was quite
consistent in these age matched 3xTgAD mice across the group. These findings address the
application of delivery of therapeutic protein, MBP; either through anticipated GM1 mediated
receptor binding to the pentameric CTB of the fusion protein in the BBB or through
compromised BBB in the AD model of transgenic mice allowing more BBB permeability for
CTB-MBP delivery.
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Figure 4: Oral delivery of CTB-MBP chloroplast expressed protein decreased the amyloid
plaque burden in a mouse model of AD.
Representative images (a, b) of the cortical and hippocampal amyloid plaque burden in 3xTg AD
mice fed 3 times weekly over 12 weeks starting at 13-15 months of age with either recombinant
CTB-MBP protein transgenic leaf extracts (31.2ug/300ul/day; n=10 mice, untransformed (WT)
leaf extracts (300ul/day; n=4 mice), or

unfed (n=4 mice). Sections were stained for amyloid

plaques with either anti- Aβ antibody 2454 (red fluorescence; a) or Thioflavin S (green
fluorescence; b) and with DAPI (blue) to label cell nuclei. Scale bar: hippocampus 100um (i) and
10um (ii) at different magnification, cortex 10um (iii)) (c) Quantification of the relative amounts
of amyloid plaque load in the anti- Aβ stained sections from the animals treated with CTB-MBP
and WT protein extracts as described in (a). (d) Quantification of the relative amounts of amyloid
plaque number and intensity in the thioflavinS stained sections from the animals treated with
CTB-MBP and WT protein extracts as described in (b). The mean plaque counts in the DG, CA1
and CA3 hippocampal and (mantle and pallium regions) cortical regions per section were
determined with NIS Elements for Advanced Research. Data shown is mean ± S.D of values
obtained from five adjacent sections per mouse and five fields per section. Single factor ANOVA
*p<0.05, **p<0.01, compared to mice treated with WT leaf extracts and unfed.
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CHAPTER FOUR: DISCUSSION

This study shows efficient in vivo oral delivery of chloroplast expressed CTB-MBP
fusion protein across BBB. The native confirmation of CTB pentamers facilitates binding to the
intestinal GM1 receptors and effectively release the fused protein to the circulatory system when
orally administered (35). CTB ensures the stability of fused protein through its pentameric
confirmation. This work provides evidence for transport and efficient delivery of CTB fusion
protein across BBB. Moreover, our findings support therapeutic MBP delivery into the brain in
vivo potentially to reduce amyloid aggregates. Previous studies show presence of GM1 receptors
on the BBB (36). The delivery of plant derived CTB-fusion protein can be anticipated to occur
by GM1 receptor mediation through CTB-GM1 interaction on BBB, but additional experiments
are required to address this mechanism. Moreover, BBB impairment is associated with more
rapid progression in AD over 1 year (39). Clinical studies show that BBB is compromised in AD
brains (40). With the damage of anatomical organization of BBB we anticipate increased BBB
permeability, facilitating delivery of therapeutic proteins across BBB, further enhancing their
delivery. Likewise, ability of bioencapsulated CTB-MBP to reduce amyloid levels in vivo
indicates another path of efficient delivery of protein across disrupted BBB from site of
administration, while maintaining its functional and structural integrity. This provides an
inexpensive plant based application of delivering therapeutic protein across BBB.
Both widespread and diffused myelin breakdown (41) in the brains has been reported in
patients with AD. Correlation of amyloid deposition with destruction of myelin also contributes
the progression of age dependent AD (42). Myelin basic protein covers the myelin membranes
and holds the lipid bilayer through electrostatic interactions in the CNS (43), ensuring its
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importance in myelination and neurotransmission processes. Along with serine 151 residue
serving as an active site for autocatalysis in MBP, its ability to interact with Aβ peptides, or
degradation of fibril amyloid deposits have been previously discussed based on in vitro studies
(15, 17, 18), consistent with our study and showing the capability of MBP to degrade Aβ.
This study also shows an optimal reduction up to 48% of thioflavin S stained amyloid
deposits in advanced human AD post mortem brain sections, when incubated with chloroplast
derived MBP. The significant reduction in human brains insights the functional degrading
activity of plant expressed MBP ex vivo. Due to limited availability of human brain sections,
anti-Aβ immunostaining could not be performed. Although in each brain section, obtained from
different individual suffering with Alzheimer’s disease at an advanced stage, consistent ThS
staining reduction was noticed upon incubation. Moreover, with a higher purity of plant derived
MBP, more effective degradation results could have been observed.
We observed a concentration-dependent degradation and/or reduction of amyloid levels
of up to 66% in the brains of old 3xTg AD mice upon MBP incubation. Therefore, in this study,
our investigations focus on the role of MBP to reduce the amyloid levels in vivo in 3xTg AD
mice and ex vivo in brains of advanced AD individuals, by CTB mediated delivery of MBP that
was expressed in plant cells through chloroplast engineering. We observed that 3xTg AD mice
brain showed up to 67% and 33% decrease of amyloid levels when fed with CTB-MBP,
particularly in dentate gyrus, CA1 and CA3 regions of hippocampal and in cortical brain regions,
that are known to carry the most amyloid burden as a certain pathology in transgenic AD mice as
well as in human AD (44). Immunostaining and thioflavin fluorescence, quantified and analyzed
by fluorescence microscopy, were used to detect Aβ deposits. Moreover, thioflavin positive
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amyloid deposits were observed in the areas of anti-amyloid immunoreactivity by staining
hippocampus in adjacent brain sections in in vivo studies with anti-amyloid antibody and
thioflavin S. This study quantitatively confirms the reduction of immunoreactive amyloid
deposits in brain sections from oral delivery of CTB-MBP in old 3xTg AD mice. Histological
analyses confirms quantitative as well as qualitative reduction of Aβ accumulation pathology
through MBP in 3xTg AD mice and human AD.
Medical imaging techniques like magnetic resonance imaging (MRI) measure the
structural integrity of myelin (45). Both widespread and diffused myelin breakdown (41, 46) in
the brains has been reported in patients with AD. Correlation of amyloid deposition with
destruction of myelin also contributes the progression of age dependent AD (42, 47). Studies
report that slow myelin turnover rate could occur (48) because oligodendrocytes in the central
nervous system (CNS) may differentiate in the brain development process with condensed
myelin repair ability, thereby contributing to myelin degeneration.
Another hallmark of AD observed in 3xTgAD mice is neurofibrillary tangles that
comprise of tau proteins (49) which are pathologic in their hyper-phosphorylated state and
appears after Aβ deposition. It is possible that contribution of these tangles towards pathology
may be reduced by MBP and hence demands further investigations for their reduction in brains
of AD patients and transgenic mice model. In addition, the clearance of amyloid load in our
investigation also warrants further behavioral studies in 3xTgAD mice over a long term period
by oral delivery of bioencapsulated CTB-MBP. However, behavioral changes should be
investigated in mice, fed with plant material simultaneously, at an early age of developing AD.
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Recent findings suggest that Aβ accumulation is related to stress-induced senescence of
astrocytes (50), by losing their ability for homeostasis maintenance in CNS. It remains to be
determined from our findings if clearance of Aβ from brain would decrease astrocytes
senescence, which contributes to pathogenesis and progression of AD (50). In addition, it has
been suggested that zinc sequestration by Aβ deposits is susceptible to AD pathology (51), by
inducing Aβ aggregation and disturbing zinc homeostasis. The therapeutic approach suggested
by our investigations could also help elucidate mechanistic approaches for zinc distribution
associated with pathology in AD.
Active and passive immunotherapies have been reported to target Aβ in clinical studies
(11) through immunization, but recent disappointment with bapineuzumab antibody in clinical
trial III calls for alternative strategy for Alzheimer’s drugs and therapies. The 2011 world
Alzheimer’s report concludes that up to 28 million people with dementia, lack efficient
diagnosis, treatment and care (52), increasing the “treatment gap” from high to low and middle
income countries Not only the need for novel strategies are needed but also the urge to halt it at
an initial stage will be proven beneficial (53). Our lab used genetically engineered plants for
expression and oral delivery of proinsulin (29), insulin and C peptide (30), exendin 4 (25) for
treatment of diabetes or blood clotting factor IX for hemophilia B (31). Here we report
expression of CTB fused with MBP in tobacco plant chloroplasts and their expression as a fusion
protein. Lyophilization of leaf materials increases concentration of bioencapsulated transgenic
protein for oral delivery. Lyophilization of plant cells increased CTB-MBP concentration,
resulting in CTB-MBP capsules to be stored at room temperature for several months without any
degradation of therapeutic protein. Oral delivery of therapeutic protein MBP, through GM1
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receptor mediated delivery of CTB to the circulatory system and to the brain across the blood
brain barrier in the AD model of transgenic mice in vivo and in advanced human AD brains ex
vivo, opens the door for a novel concept and further advances in human clinical studies.
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